Company / Cash & Equivalents
Immuneering Corp Cash & Equivalents History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$59.4M
FY2023
5-year range
$59.4M / $74.9M
FY2021-FY2023
Trend
-18.2%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $75M to $59M over the past 2 years.
Based on SEC 10-K filings.
$59M in FY2023.
Declined from $75M to $59M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, cash & equivalents decreased 18.2% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $59.4M | -18.2% |
| FY2022 | $72.6M | -3.0% |
| FY2021 | $74.9M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026